{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:07:13Z","timestamp":1791317233383,"version":"4.3.1"},"reference-count":86,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1016\/j.ijantimicag.2010.10.030","type":"journal-article","created":{"date-parts":[[2011,2,7]],"date-time":"2011-02-07T09:11:16Z","timestamp":1297069876000},"page":"202-209","source":"Crossref","is-referenced-by-count":57,"title":["Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits?"],"prefix":"10.1016","volume":"37","author":[{"given":"Ian M.","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Cauda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvano","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gudiol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Mazzei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0005","unstructured":"European Antimicrobial Resistance Surveillance System Annual Report, 2008. Bilthoven, The Netherlands: National Institute for Public Health and the Environment; 2009."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1086\/345476","article-title":"Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis","volume":"36","author":"Cosgrove","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0015","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1086\/379321","article-title":"Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia","volume":"37","author":"Melzer","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0020","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/512627","article-title":"Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus","volume":"28","author":"Shurland","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0025","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1183\/09031936.00081007","article-title":"Impact of methicillin resistance on mortality in Staphylococcus aureus VAP: a systematic review","volume":"28","author":"Athanassa","year":"2008","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1469-0691.2009.02701.x","article-title":"Management of methicillin-resistant Staphylococcus aureus infections","volume":"15","author":"Garau","year":"2009","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/jac\/dkp456","article-title":"A survey of attitudes towards methicillin-resistant Staphylococcus aureus bacteraemias amongst United Kingdom microbiologists","volume":"65","author":"Hussain","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0040","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1086\/518452","article-title":"Counterpoint: Vancomycin and Staphylococcus aureus\u2014an antibiotic enters obsolescence","volume":"44","author":"Deresinski","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0045","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1086\/518451","article-title":"Point: Vancomycin is not obsolete for the treatment of infection caused by methicillin-resistant Staphylococcus aureus","volume":"44","author":"Mohr","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0050","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0012-3692(15)33412-7","article-title":"Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"124","author":"Wunderink","year":"2003","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0055","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1007\/s00134-003-2088-1","article-title":"Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin","volume":"30","author":"Kollef","year":"2004","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0060","doi-asserted-by":"crossref","first-page":"3883","DOI":"10.1128\/JCM.01388-06","article-title":"Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period","volume":"44","author":"Wang","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0065","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0070","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1128\/AAC.00945-07","article-title":"Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006","volume":"52","author":"Holmes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2010.10.030_bib0075","first-page":"ii65","article-title":"Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001\u201306","volume":"62","author":"Hope","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0080","doi-asserted-by":"crossref","first-page":"4528","DOI":"10.1128\/AAC.00904-08","article-title":"Vancomycin MICs for methicillin-resistant Staphylococcus aureus isolates differ based upon the susceptibility test method used","volume":"52","author":"Prakash","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0085","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1128\/AAC.00093-09","article-title":"Nine-hospital study comparing broth microdilution and E-test method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus","volume":"53","author":"Sader","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0090","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1128\/AAC.01365-08","article-title":"Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA","volume":"53","author":"Horne","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0095","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1086\/606027","article-title":"Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance","volume":"200","author":"Bae","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0100","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1086\/596629","article-title":"Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia","volume":"199","author":"Maor","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0105","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1086\/381093","article-title":"Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus","volume":"38","author":"Charles","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0110","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/381202","article-title":"Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility","volume":"38","author":"Howden","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0115","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/jac\/dkn246","article-title":"Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage","volume":"62","author":"Al\u00f3s","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0120","series-title":"49th Interscience Conference on Antimicrobial Agents And Chemotherapy (ICAAC), 12\u201315 September 2009","article-title":"Secular trends in the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in a university hospital","author":"Gasch","year":"2009"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2010.10.030_bib0125","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1086\/491710","article-title":"Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal\/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains","volume":"42","author":"Jones","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0130","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/jac\/dkm445","article-title":"Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"61","author":"Moise","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0135","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27\u201330 September 2006","article-title":"Relationship of prior vancomycin use and daptomycin MICs in patients with MRSA bacteremia","author":"Moise-Broder","year":"2006"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0140","unstructured":"Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0145","unstructured":"European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 1.0. Basel, Switzerland: EUCAST; 2009."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0155","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1128\/JCM.42.6.2398-2402.2004","article-title":"Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"42","author":"Sakoulas","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0160","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1001\/archinte.166.19.2138","article-title":"High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity","volume":"166","author":"Hidayat","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0165","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1128\/AAC.00939-06","article-title":"Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia","volume":"51","author":"Moise","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0170","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1128\/AAC.00113-08","article-title":"Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0175","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1086\/524667","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0180","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ijantimicag.2008.05.007","article-title":"Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections","volume":"32","author":"Hsu","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0185","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0190","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1378\/chest.130.4.947","article-title":"Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices","volume":"130","author":"Jeffres","year":"2006","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0195","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1086\/600884","article-title":"Relationship between initial vancomycin concentration\u2013time profile and nephrotoxicity among hospitalized patients","volume":"49","author":"Lodise","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0200","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1128\/AAC.01602-07","article-title":"Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity","volume":"52","author":"Lodise","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0205","doi-asserted-by":"crossref","first-page":"390","DOI":"10.7326\/0003-4819-117-5-390","article-title":"Trimethoprim\u2013sulfamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection","volume":"117","author":"Markowitz","year":"1992","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0210","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa053783","article-title":"Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus","volume":"355","author":"Fowler","year":"2006","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"10.1016\/j.ijantimicag.2010.10.030_bib0215","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1086\/590937","article-title":"Health care-associated infection (HAI): a critical appraisal of the emerging threat\u2014proceedings of the HAI Summit","volume":"47","author":"Kollef","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0220","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0225","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jac\/dkq009","article-title":"Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK","volume":"65","author":"Kirby","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00003088-200039030-00001","article-title":"Clinical pharmacokinetics of teicoplanin","volume":"39","author":"Wilson","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0235","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/AAC.39.8.1842","article-title":"Protein binding and serum bactericidal activities of vancomycin and teicoplanin","volume":"39","author":"Dykhuizen","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0240","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijantimicag.2009.09.013","article-title":"Linezolid versus vancomycin for the treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"35","author":"Beibei","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0250","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S1473-3099(07)70312-2","article-title":"Linezolid versus glycopeptide or \u03b2-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials","volume":"8","author":"Falagas","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0255","series-title":"46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 27\u201330 September 2006","article-title":"Linezolid (Lin) serum levels: one size doesn\u2019t fit all!","author":"Goldstein","year":"2006"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0260","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijantimicag.2007.09.009","article-title":"Linezolid pharmacokinetic\/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion","volume":"31","author":"Adembri","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0265","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/jac\/dkm369","article-title":"Linezolid versus vancomycin for the treatment of infections caused by methicillin-resistant Staphylococcus aureus in Japan","volume":"60","author":"Kohno","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0270","unstructured":"US Food and Drug Administration. Information for healthcare professionals: linezolid (marketed as Zyvox). Silver Spring, MD: FDA; 16 March 2007."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0275","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.diagmicrobio.2008.10.010","article-title":"United States resistance surveillance results for linezolid (LEADER Program for 2007)","volume":"62","author":"Jones","year":"2008","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0280","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1128\/AAC.00131-06","article-title":"The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics","volume":"50","author":"Long","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0285","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1128\/JCM.01886-07","article-title":"Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase","volume":"46","author":"Arias","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0290","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1128\/AAC.00231-08","article-title":"First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States","volume":"52","author":"Mendes","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0295","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"S\u00e1nchez Garc\u00eda","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0300","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10156-009-0727-3","article-title":"Linezolid-resistant methicillin-resistant Staphylococcus aureus isolated after long-term, repeated use of linezolid","volume":"15","author":"Yoshida","year":"2009","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0305","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/jac\/dkn372","article-title":"Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates","volume":"62","author":"Rehm","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0310","doi-asserted-by":"crossref","first-page":"5141","DOI":"10.1128\/AAC.00307-09","article-title":"Correlation between vancomycin MIC values and those of other agents against Gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus","volume":"53","author":"Patel","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0315","doi-asserted-by":"crossref","first-page":"5285","DOI":"10.1128\/JCM.43.10.5285-5287.2005","article-title":"Development of daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus","volume":"43","author":"Hayden","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.00719-07","article-title":"Failures in clinical treatment of Staphylococcus aureus infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding","volume":"52","author":"Jones","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0325","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1128\/AAC.01682-08","article-title":"Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus","volume":"53","author":"Mishra","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0330","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0335","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1345\/aph.1M085","article-title":"Safety and clinical outcomes when utilizing high-dose (\u22658mg\/kg) daptomycin therapy","volume":"43","author":"Moise","year":"2009","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0340","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1586\/eri.09.121","article-title":"A simplified three-times weekly daptomycin dosing regimen for chronic hemodialysis patients","volume":"8","author":"Burkhardt","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0345","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/ndt\/gfp655","article-title":"Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients","volume":"25","author":"Salama","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0350","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1179\/joc.2010.22.1.13","article-title":"Sustained antimicrobial activity of tigecycline against methicillin-resistant Staphylococcus aureus (MRSA) from United States medical centers from 2004 through 2008","volume":"22","author":"Putnam","year":"2010","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0355","series-title":"48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25\u201328 October 2008","article-title":"Efficacy and safety of fosfomycin (F) plus imipenem (I) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) native valve endocarditis (NVE): preliminary results of a clinical trial","author":"M\u00edro","year":"2008"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0360","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1086\/587896","article-title":"Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms","volume":"46","author":"Stryjewski","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0365","unstructured":"Pfizer Inc. Pfizer will withdraw global marketing applications for dalbavancin to conduct a new trial. Pfizer press release. 9 September 2008 http:\/\/www.businesswire.com\/portal\/site\/pfizer\/permalink\/?ndmViewId=news_view&newsId=20080909005943&newsLang=en [accessed 30 November 2010]."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0370","unstructured":"European Medicines Agency. Questions and answers on the withdrawal of the marketing authorisation application for Ramvocid (oritavancin). EMEA\/554626\/2009. London, UK: EMEA; 24 September 2009."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0375","unstructured":"Johnson & Johnson. FDA issues complete response letter for ceftobiprole. Press release. 30 December 2009. Raritan, NJ: Johnson & Johnson; 2009 http:\/\/www.jnj.com\/connect\/news\/all\/20091230_090000 [accessed 10 May 2010]."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0380","unstructured":"European Medicines Agency. Questions and answers: refusal of the marketing approval for Zeftera (ceftobiprole). EMA\/83783\/2010. London, UK: EMEA; 18 February 2010."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0385","series-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 25\u201328 October 2008","article-title":"Ceftobiprole versus ceftazidime combined with linezolid for treatment of patients with nosocomial pneumonia","author":"Noel","year":"2008"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0390","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1128\/AAC.01516-09","article-title":"In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates","volume":"54","author":"Saravolatz","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0395","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dkq193","article-title":"Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0400","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1093\/jac\/dkq328","article-title":"Evaluation of the in vivo efficacy of intramuscularly administered ceftaroline fosamil, a novel cephalosporin, against a methicillin-resistant Staphylococcus aureus strain in a rabbit endocarditis model","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0405","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1086\/655827","article-title":"Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection","volume":"51","author":"Corey","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0410","unstructured":"Arpida. Arpida withdraws European marketing application for intravenous iclaprim in cSSTI as a result of negative outcome of CHMP hearing. Press release 20 October 2009. Reinach, Switzerland: Evolva\/Arpida; 2009. http:\/\/www.evolva.com\/newsroom\/2009\/10\/20\/53\/arpida-withdraws-european-marketing-application-intravenous-iclaprim-cssti-re [accessed 1 May 2010]."},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0435","article-title":"Update on screening and clinical diagnosis of meticillin-resistant Staphylococcus aureus","author":"Harbarth","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0440","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijantimicag.2010.10.023","article-title":"Meticillin-resistant Staphylococcus aureus (MRSA): Screening and de-colonisation","volume":"37","author":"Cookson","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0425","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1086\/597031","article-title":"Initial low-dose gentamicin for Staphylococcus aureus bacteremia and endocarditis is nephrotoxic","volume":"48","author":"Cosgrove","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2010.10.030_bib0430","series-title":"48th Annual Meeting of the Infectious Diseases Society of America (IDSA), 21\u201324 October 2010","article-title":"Linezolid vs vancomycin in the treatment of nosocomial pneumonia proven due to methicillin-resistant Staphylococcus aureus","author":"Kunkel","year":"2010"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910005327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857910005327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:59:00Z","timestamp":1543971540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857910005327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":86,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0924857910005327"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.10.030","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}